Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Parnassus Growth Equity Fund. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
QTD+17.49%
YTD+6.17%
Annualized+26.63%
Positioning StanceNEUTRAL
Market CapLarge Cap
GeographyUS
Digest Analysis
Quick Take
"Parnassus Growth Equity outperformed in Q2 2026 on strong semiconductor and AI infrastructure holdings, rotating capital into biotechnology and data center positions with clearer growth paths."
Executive Summary
Parnassus Growth Equity Fund returned 17.49% in Q2 2026, outperforming the Russell 1000 Growth Index's 16.74%, driven by strong performance in Information Technology and Consumer Discretionary holdings. The fund's semiconductor positions were top contributors as AI infrastructure demand continued to climb, with Applied Materials, AMD, ASML, and TSMC all benefiting from investor confidence in sustained AI spending. During the quarter, managers rotated out of six positions into five new ones offering clearer growth paths, adding exposure to biotechnology (Twist Bioscience, Revolution Medicines), data center infrastructure (Lumentum, Comfort Systems), and flash memory (Sandisk). The managers remain constructively bullish on U.S. equities while acknowledging heightened market concentration and mixed macroeconomic conditions including trade tensions, inflation pressures, and higher interest rates. They view AI as a structurally disruptive force distinct from the dot-com bubble and continue to seek disruptive innovation capable of growing through various macroeconomic environments. The fund maintains a balanced portfolio between offense and defense, selectively participating in secular trends at attractive valuations through active stock selection.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
Market Conviction
68%
CautiousHigh
Moderate (68%)
The fund runs a concentrated portfolio with clear position sizing evident in the top 10 holdings (ranging from 3.1% to 11.6%). Managers name specific positions and explain detailed theses for each buy and sell decision. They rotated six positions into five new ones with explicit rationale for each, demonstrating active conviction-driven portfolio management. However, the fund holds approximately 40-50 positions based on the sector weights and diversification across multiple themes, which prevents a higher conviction score. The language is decisive about specific holdings but acknowledges uncertainty in the macro environment, placing this in the moderate-to-high conviction range.
Growth Outlook
45%
BearishBullish
Neutral (45%)
The managers describe themselves as 'constructively bullish' on U.S. equities while acknowledging they are 'more cautious now than we were in January.' They view AI as a structurally disruptive force with years of runway ahead, distinguishing it from the dot-com bubble. However, they flag heightened market concentration, mixed macroeconomic conditions including trade tensions and inflation, and note that 'the fact that so much of the market return and earnings growth has been concentrated in a narrow group of companies calls for caution.' The outlook is positive but tempered with meaningful caveats, scoring in the mildly positive range.
Risk Appetite
55%
DefensiveAggressive
Balanced (55%)
The fund maintains 'a portfolio balanced between offense and defense' with only 0.7% cash, indicating near-full investment. Managers 'have taken advantage of ongoing market volatility to selectively participate in secular trends at attractive valuations' in AI beneficiaries. They rotated out of six positions into five new ones during the quarter, demonstrating active deployment into higher-conviction ideas. The positioning is tilted toward risk with concentrated exposure to semiconductors and AI infrastructure, but the language around 'selective' and 'valuation-sensitive' suggests measured rather than maximum aggression.
Capital Deployment
15%
De-riskingDeploying
De-risking (15%)
Cash remained minimal at 0.7% of assets, indicating the fund stayed near-fully invested throughout the quarter. The managers rotated capital by selling six positions and buying five new ones, but this represents capital rotation rather than net new deployment. There is no evidence of cash levels declining or the fund adding net new risk exposure. The rotation activity demonstrates active management but not net deployment or de-risking, scoring near neutral with a slight positive bias for the active reallocation into higher-conviction ideas.
Forward Guidance
40%
CautiousExpansionary
Neutral (40%)
The managers state they 'continue to seek opportunities to invest in innovative, increasingly relevant, competitively advantaged businesses at attractive valuations' and will 'continue to be selective, valuation-sensitive and focused on quality growth opportunities through active stock selection.' The language indicates ongoing deployment bias but with significant selectivity and valuation discipline. They are watching for opportunities rather than aggressively deploying, and the emphasis on 'selective' and 'valuation-sensitive' suggests a measured approach to adding new positions.
Language Signal
50%
BearishBullish
Balanced (50%)
The letter contains substantial bullish language around AI as a 'structurally disruptive force,' 'durable high-growth healthcare themes,' 'compelling long-term idiosyncratic growth opportunities,' and 'attractive valuations.' However, this is balanced with cautionary language including 'calls for caution,' 'heightened concentration,' 'mixed macroeconomic backdrop,' 'trade tensions,' 'inflation pressures,' and 'reduced visibility.' The managers use phrases like 'more cautious now' and note multiple risk factors. The net balance is moderately positive but not overwhelmingly bullish.
Perceived Risk
58%
Low RiskElevated
Moderate Risk (58%)
The managers identify multiple specific risks including market concentration at levels not seen since 1999, trade tensions with China, inflation pressures from higher oil prices, higher-than-expected interest rates, and the Iran War. They note these factors 'would normally exert pressure' on markets and that 'the fact that so much of the market return and earnings growth has been concentrated in a narrow group of companies calls for caution.' However, the risk discussion is balanced rather than alarmed, and managers frame some risks as manageable through selectivity. The level of risk acknowledgment is meaningful but not systemic or tail-risk focused.
Opportunity Density
62%
ScarceAbundant
Selective (62%)
The managers describe 'compelling long-term idiosyncratic growth opportunities' in healthcare and state they 'continue to seek opportunities to invest in innovative, increasingly relevant, competitively advantaged businesses at attractive valuations.' They successfully identified five new positions to add during the quarter across biotechnology, data centers, and semiconductors. However, they also note that 'heightened concentration makes participating far more challenging than the headline index returns suggest' and emphasize the need to be 'selective' and 'valuation-sensitive,' indicating opportunities exist but require careful screening rather than being abundant across the market.
Time Horizon
72%
Short-TermLong-Term
Decade+ (72%)
The fund's stated objective is 'strong long-term returns' and managers consistently reference 'long-term secular trends,' 'durable high-growth healthcare themes,' and 'long-term competitive positioning.' They describe AI as having 'years to run' and discuss 'enduring value for our investors.' The investment rationale for new positions focuses on multi-year growth runways (e.g., 'longer runway for growth' for Twist Bioscience). However, the fund also responds to quarterly results and near-term competitive dynamics (exiting Boston Scientific due to 'reduced visibility into a near-term reacceleration'), indicating a 2-4 year rather than decade-plus horizon. The time horizon is clearly multi-year but not permanent capital.